APA (7th ed.) Citation

M, S., K, M., T, N., T, H., M, S., K, K., . . . E, O. (2026). Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity. Cureus, 18(5), e108385. https://doi.org/10.7759/cureus.108385

Chicago Style (17th ed.) Citation

M, Saburi, Maehara K, Nishikawa T, Hiroyuki T, Sakata M, Kohno K, Ogata Y, Haruyama T, and Ohtsuka E. "Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity." Cureus 18, no. 5 (2026): e108385. https://doi.org/10.7759/cureus.108385.

MLA (9th ed.) Citation

M, Saburi, et al. "Treatment Discontinuation of First-Line Bosutinib in a Real-World Cohort of Patients With Chronic Myeloid Leukemia: Impact of Hepatic Toxicity." Cureus, vol. 18, no. 5, 2026, p. e108385, https://doi.org/10.7759/cureus.108385.